TY - JOUR
T1 - Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy
T2 - A case report and review of the literature
AU - Brzezinska, Bogna N.
AU - Higgins, Robert V.
AU - Rungruang, Bunja
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/5
Y1 - 2021/5
N2 - Background: Use of immune checkpoint inhibitors in treatment of gynecologic malignancies is increasing. Rare, but potentially fatal, immune-related neurologic adverse events may occur as a result of treatment. Case: A 72 year old female with recurrent metastatic uterine adenocarcinoma received pembrolizumab and lenvatinib combination therapy. Following her second dose of pembrolizumab, the patient developed multiple neurologic symptoms. She was ultimately diagnosed with Guillain-Barre Syndrome based on neurologic evaluation with imaging, serum studies, and cerebrospinal fluid analysis. The patient was successfully treated with high-dose intravenous corticosteroids and intravenous immunoglobulin. Conclusion: Neurologic complications related to immune checkpoint inhibitor therapy are rare. It is imperative for gynecologic oncologists to be familiar with potentially fatal hazards of therapy to allow for rapid diagnosis and treatment.
AB - Background: Use of immune checkpoint inhibitors in treatment of gynecologic malignancies is increasing. Rare, but potentially fatal, immune-related neurologic adverse events may occur as a result of treatment. Case: A 72 year old female with recurrent metastatic uterine adenocarcinoma received pembrolizumab and lenvatinib combination therapy. Following her second dose of pembrolizumab, the patient developed multiple neurologic symptoms. She was ultimately diagnosed with Guillain-Barre Syndrome based on neurologic evaluation with imaging, serum studies, and cerebrospinal fluid analysis. The patient was successfully treated with high-dose intravenous corticosteroids and intravenous immunoglobulin. Conclusion: Neurologic complications related to immune checkpoint inhibitor therapy are rare. It is imperative for gynecologic oncologists to be familiar with potentially fatal hazards of therapy to allow for rapid diagnosis and treatment.
KW - Guillain-Barre Syndrome
KW - Immune-related adverse events
KW - Immunotherapy
KW - Pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85107903156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107903156&partnerID=8YFLogxK
U2 - 10.1016/j.gore.2021.100739
DO - 10.1016/j.gore.2021.100739
M3 - Article
AN - SCOPUS:85107903156
SN - 2211-338X
VL - 36
JO - Gynecologic Oncology Reports
JF - Gynecologic Oncology Reports
M1 - 100739
ER -